CN Mobile Logo

Search form


First Results of Avicidin Trials

First Results of Avicidin Trials

SEATTLE--NeoRx Corporation reports that in phase I/II dose escalation studies, Avicidin produced a 10-fold improvement in tumor-to-blood ratios over conventional radioimmunotherapy, approaching the ratios achieved in animal studies.

Avicidin, a monoclonal antibody/yttrium-90 product, employs NeoRx's proprietary pretargeting technology in which the radionuclide and antibody are injected separately rather than linked together. The radionuclide either attaches to the antibody that is pretargeted to the tumor or quickly exits the body, reducing radiation exposure to normal tissues, NeoRx said.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.